Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer
November 08 2017 - 7:30AM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced the appointment of David Recker, MD, FACR, FACP, as Chief
Medical Officer.
“Given his extensive experience in the biopharma industry, Dr.
Recker brings to Neuralstem an expertise that will be critical to
the development of our clinical and preclinical pipeline,
especially as we continue to plan our path forward,” said Rich
Daly, Chairman and CEO, Neuralstem. “Dr. Recker has managed
execution of all elements of clinical strategy, including trial
development, data interpretation and product registration. These
qualifications among myriad others make him an excellent addition
to our organization.”
Dr. David Recker is the founding manager of JJK Consulting, a
group that advises on pharmaceutical development, with an emphasis
on global implementation of small molecule clinical trial design as
well as a therapeutic focus on cell therapy. Dr. Recker serves as
the Chief Medical Officer of Vericel Corporation, where he has been
responsible for clinical development, regulatory affairs, medical
and scientific affairs, pharmacovigilance, statistics and data
management. Previously, Dr. Recker was Senior Vice President,
Clinical Sciences with Takeda’s Global Research and Development
division, where he implemented global clinical development
strategies for several pharmacologic agents in multiple therapeutic
areas. Dr. Recker completed his M.D. with distinction at the
University of Michigan Medical School.
About Neuralstem Neuralstem is a clinical-stage
biopharmaceutical company developing novel treatments for nervous
system diseases of high unmet medical need. NSI-189 is a
small molecule in clinical development for major depressive
disorder (MDD) and in preclinical development for Angelman
syndrome, irradiation-induced cognitive impairment, Type 1 and Type
2 diabetes, and stroke.
NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, chronic spinal cord injury (cSCI) and
Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified
portfolio of product candidates is based on its proprietary neural
stem cell technology.
Cautionary Statement Regarding Forward Looking
InformationThis news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and Form 10-Q for the three months
ended March 31, 2017, filed with the Securities and Exchange
Commission (SEC), and in other reports filed with the SEC. We do
not assume any obligation to update any forward-looking
statements.
Contact:
Kimberly MinarovichArgot Partners (Investor
Relations)212-600-1902kimberly@argotpartners.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024